Ventilator-Associated Pneumonia (VAP). Pneumonia, unspecified organism
Conditions
Interventions
Intervention 1: Patients in this group receive Femilact® tablets (manufactured by Zist Takhmir Co.) twice daily. Each tablet contains 10? CFU of probiotics (Lactobacillus rhamnosus, Bifidobacterium la
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients aged 18 years or older Patients undergoing mechanical ventilation No prior administration of antibiotics effective against common VAP-associated strains Non-pregnant and non-lactating patients Absence of underlying chronic pulmonary diseases such as asthma or COPD Absence of immunocompromising conditions or immunosuppressive therapy; patients not undergoing hemodialysis No known history of hypersensitivity to any components of the synbiotic FamiLact®
Exclusion criteria
Exclusion criteria: Patient or family unwillingness to continue participation in the study Transfer to another healthcare facility or discharge from the ICU within less than 5 days Inability to receive the probiotic within the first 48 hours of intubation, regardless of cause History of gastrectomy, esophagectomy, pancreatectomy, gastric bypass, gastric banding, or short bowel syndrome Administration of broad-spectrum antibiotics or diagnosis of infections due to causes other than ventilator-associated pneumonia (VAP)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temperature. Timepoint: Duraing the study. Method of measurement: Thermometer.;Pulmonary secretions. Timepoint: During the study. Method of measurement: Chest buttle, Observation by an intensive care unit nurse.;White blood cell. Timepoint: During the study. Method of measurement: Laboratory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of days of hospitalisation. Timepoint: The first and last day of the study. Method of measurement: Medical record.;Blood creatinine level. Timepoint: During the study. Method of measurement: Laboratory.;Blood culture. Timepoint: During the study. Method of measurement: Laboratory.;Blood Urea Nitrogen. Timepoint: During the study. Method of measurement: Laboratory.;Arterial blood gas test. Timepoint: During the study. Method of measurement: Measurement using arterial blood sampling and a blood gas analyser.;Bilirubin. Timepoint: During the study. Method of measurement: Laboratory.;Lactate. Timepoint: During the study. Method of measurement: Laboratory.;Alanine Aminotransferase. Timepoint: During the study. Method of measurement: Laboratory.;Aspartate Aminotransferase. Timepoint: During the study. Method of measurement: Laboratory.;Heart Rate. Timepoint: During the study. Method of measurement: Assessment through electrocardiographic (ECG) monitoring.;Creatinine Clearance. Timepoint: During the study. Method of measurement: Calculation using standard creatinine clearance formula and measurement of serum creatinine level in the laboratory.;Blood pressure. Timepoint: During the study. Method of measurement: Digital blood pressure monitor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Sahraei
Shahid Beheshti University of Medical Sciences
Outcome results
None listed